Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-11-6
pubmed:abstractText
The cytotoxicity and chemosensitizing potential of four dual function nitrofurans was determined in human HT-29 multi-cell spheroids and rodent KHT sarcoma solid tumors. Spheroids were treated with a range of doses of the bioreductive drugs for a period of up to 48 h and the extent of cell kill was assessed at various times after treatment. Cytotoxicity was determined using a clonogenic cell-survival assay. The results demonstrated that two of the nitrofurans were even more toxic to spheroid cells than was the potent bioreductive nitroimidazole aziridine RSU 1069. The dose of the nitrofuran which, after a 24-h exposure, led to a survival value between 0.5 and 1.0, then was chosen for subsequent studies aimed at assessing the ability of these agents to potentiate the efficacy of the nitrosourea CCNU. Exposure to this chemotherapeutic agent was for a period of 1 h. The results indicated that all four dual function nitrofurans enhanced the cell killing of the conventional chemotherapeutic agent by factors ranging from 1.1 to 1.7. Subsequent studies evaluated the therapeutic benefit of combining these bioreductive agents and CCNU in KHT sarcoma-bearing C3H/HeJ mice. The nitrofurans were administered i.p. 0.5 h prior to the chemotherapy and tumor response was assessed by measuring the survival of clonogenic KHT cells 22-24 h after treatment. Normal tissue toxicity was determined using a bone marrow stem cell (CFU-GM) assay. Combining these bioreductive agents with CCNU increased the tumor cell kill by factors of 1.2 to 1.7.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/1-(2-nitro-1-imidazolyl)-3-aziridino..., http://linkedlifedata.com/resource/pubmed/chemical/2,3-epoxypropyl-5-nitrofuran-2-carbo..., http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aziridines, http://linkedlifedata.com/resource/pubmed/chemical/Lomustine, http://linkedlifedata.com/resource/pubmed/chemical/Misonidazole, http://linkedlifedata.com/resource/pubmed/chemical/N-(2,3-epoxypropyl)-3-(5-nitrofuran-..., http://linkedlifedata.com/resource/pubmed/chemical/Nitrofurans, http://linkedlifedata.com/resource/pubmed/chemical/RB 88712, http://linkedlifedata.com/resource/pubmed/chemical/RB 88716, http://linkedlifedata.com/resource/pubmed/chemical/RSU 1164, http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0167-8140
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
239-45
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:1410579-Animals, pubmed-meshheading:1410579-Antineoplastic Agents, pubmed-meshheading:1410579-Aziridines, pubmed-meshheading:1410579-Bone Marrow, pubmed-meshheading:1410579-Carcinoma, pubmed-meshheading:1410579-Cell Survival, pubmed-meshheading:1410579-Dose-Response Relationship, Drug, pubmed-meshheading:1410579-Drug Synergism, pubmed-meshheading:1410579-Female, pubmed-meshheading:1410579-Humans, pubmed-meshheading:1410579-Lomustine, pubmed-meshheading:1410579-Mice, pubmed-meshheading:1410579-Mice, Inbred C3H, pubmed-meshheading:1410579-Mice, Inbred Strains, pubmed-meshheading:1410579-Misonidazole, pubmed-meshheading:1410579-Nitrofurans, pubmed-meshheading:1410579-Radiation-Sensitizing Agents, pubmed-meshheading:1410579-Sarcoma, Experimental, pubmed-meshheading:1410579-Stem Cells, pubmed-meshheading:1410579-Tumor Cells, Cultured
pubmed:year
1992
pubmed:articleTitle
Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
pubmed:affiliation
Tumor Biology Division, University of Rochester Cancer Center, New York 14642.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.